# INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

> **NCT03424122** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 50 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Parsaclisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03424122
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-06-27
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03424122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03424122, "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03424122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*